Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Commitment and Contingencies (Details)

v3.6.0.2
Note 14 - Commitment and Contingencies (Details)
 6 Months Ended 12 Months Ended
Jul. 20, 2016
USD ($)
Aug. 01, 2015
USD ($)
Oct. 01, 2014
USD ($)
Nov. 30, 2016
USD ($)
Nov. 30, 2015
USD ($)
May 31, 2016
USD ($)
shares
Feb. 29, 2016
ft²
a
Note 14 - Commitment and Contingencies (Details) [Line Items]              
Debt Conversion, Original Debt, Amount       $ 250,000 $ 0    
Employee-related Liabilities, Current       91,250   $ 267,493  
Allocated Share-based Compensation Expense       0 109,167    
Chief Executive Officer [Member]              
Note 14 - Commitment and Contingencies (Details) [Line Items]              
Employment Agreement, Term     5 years        
Officers' Compensation     $ 150,000     150,000  
Deferred Compensation Arrangement with Individual, Description     performance bonus equal to 2% of CLS Labs’ annual EBITDA, up to a maximum annual cash compensation of $1 million (including his base salary)        
Share-based Compensation Arrangement by Share-based Payment Award, Description     annual stock options, exercisable at the fair market value of CLS Labs’ common stock on the date of grant, in an amount equal to 2% of its annual EBITDA up to $42.5 million and 4% of its annual EBITDA in excess of $42.5 million        
Employee-related Liabilities, Current       75,000   $ 250,000  
Chief Operating Officer [Member]              
Note 14 - Commitment and Contingencies (Details) [Line Items]              
Employment Agreement, Term   5 years          
Officers' Compensation   $ 150,000          
Deferred Compensation Arrangement with Individual, Description   performance bonus equal to 2% of the Company’s annual EBITDA, up to a maximum annual cash compensation of $1 million (including his base salary)          
Share-based Compensation Arrangement by Share-based Payment Award, Description   annual stock options, exercisable at the fair market value of the Company’s common stock on the date of grant, in an amount equal to 2% of its annual EBITDA up to $42.5 million and 4% of its annual EBITDA in excess of $42.5 million          
Chief Operating Officer [Member] | One Time Signing Bonus [Member]              
Note 14 - Commitment and Contingencies (Details) [Line Items]              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares) | shares           250,000  
Allocated Share-based Compensation Expense           $ 327,500  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period           1 year  
Former Officer [Member]              
Note 14 - Commitment and Contingencies (Details) [Line Items]              
Employee-related Liabilities, Current       16,250   $ 16,250  
Building [Member] | Affiliated Entity [Member]              
Note 14 - Commitment and Contingencies (Details) [Line Items]              
Area of Real Estate Property (in Square Feet) | ft²             42,392
Area of Land (in Acres) | a             1.92
Operating Leases, Rent Expense       $ 89,354 $ 118,536    
Binder Convertible Note 3 [Member] | Unpaid Accrued Salary Converted to Convertible Note [Member] | Convertible Debt [Member] | Chief Executive Officer [Member]              
Note 14 - Commitment and Contingencies (Details) [Line Items]              
Debt Conversion, Original Debt, Amount $ 250,000